HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Austin, R.J.H. Articles by Uings, I.J. Search for Related Content PubMed PubMed Citation Articles by Austin, R.J.H. Articles by Uings, I.J.

Mometasone furoate is a less specific glucocorticoid than fluticasone propionate

Depts of ¹ Asthma Cell Biology and ² Gene Expression and Protein Biochemistry, GlaxoSmithKline, Stevenage, Hertfordshire, UK

CORRESPONDENCE: I. Uings, Dept of Asthma Cell Biology, GlaxoSmithKline, Stevenage, Hertfordshire, SG1 2NY, UK. Fax: 44 1438764782. E-mail: iain.j.uings@gsk.com

Keywords: asthma, corticosteroid, fluticasone, mineralocorticoid, mometasone, progesterone

Received: December 5, 2001
Accepted July 25, 2002

Fluticasone propionate (FP) and mometasone furoate (MF) are potent synthetic corticosteroids that are widely used as anti-inflammatory agents to treat respiratory diseases. As part of the assessment of the potential for side-effects associated with their use, their activities, not only at the glucocorticoid receptor (GR) but also at the other members of the steroid nuclear receptor family, have been compared.

Cell-based functional systems were established to measure different aspects of GR function, as well as the activity at all the other steroid nuclear receptors.

The effects of MF and FP on the GR were potent and indistinguishable. Neither corticosteroid showed any activity at the oestrogen receptor, while both were weak antagonists of the androgen receptor. FP was a relatively weak agonist of the progesterone receptor but MF was a very potent agonist of the progesterone receptor, giving activity at similar concentrations to those that stimulate the GR (concentration generating 50% maximal effect (EC₅₀)=50 pM). Moreover, while FP was a weak antagonist of the mineralocorticoid receptor (concentration generating 50% maximal inhibitory effect=80 nM), MF displayed potent partial agonist activity (EC₅₀=3 nM, 30%).

Mometasone furoate is considerably less specific for the glucocorticoid receptor than fluticasone propionate, showing significant activity at other nuclear steroid receptors.

This article has been cited by other articles:

				M. Issar, S. Sahasranaman, P. Buchwald, and G. Hochhaus Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur. Respir. J., March 1, 2006; 27(3): 511 - 516. [Abstract] [Full Text] [PDF]

				M. G. Belvisi, D. S. Bundschuh, M. Stoeck, S. Wicks, S. Underwood, C. H. Battram, E.-B. Haddad, S. E. Webber, and M. L. Foster Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 568 - 574. [Abstract] [Full Text] [PDF]

				K. Biggadike, I. Uings, and S. N. Farrow Designing Corticosteroid Drugs for Pulmonary Selectivity Proceedings of the ATS, December 1, 2004; 1(4): 352 - 355. [Abstract] [Full Text] [PDF]